Page 50 - AN-3-1

Advanced Neurology Antibodies as neurodegenerative biomarkers

doi: 10.1002/cpdd.584 132. Liu-Seifert H, Siemers E, Holdridge KC, et al. Delayed-start
analysis: Mild Alzheimer’s disease patients in solanezumab
122. Black RS, Sperling RA, Safirstein B, et al. A single ascending trials, 3.5 years. Alzheimers Dement (N Y). 2015;1(2):111-121.
dose study of bapineuzumab in patients with alzheimer
disease. Alzheimer Dis Assoc Disord. 2010;24(2):198-203. doi: 10.1016/j.trci.2015.06.006
doi: 10.1097/WAD.0b013e3181c53b00 133. Samadi H, Sultzer D. Solanezumab for Alzheimer’s disease.
Expert Opin Biol Ther. 2011;11(6):787-798.
123. Salloway SP, Sperling R, Fox NC, et al. Long-term follow
up of patients with mild-to-moderate Alzheimer’s disease doi: 10.1517/14712598.2011.578573
treated with bapineuzumab in a Phase III, open-label, 134. Nisticò R, Novakovic D, Feligioni M, et al. Profile of
extension study. J Alzheimers Dis. 2018;64(3):689-707. gantenerumab and its potential in the treatment of
doi: 10.3233/JAD-171157 Alzheimer’s disease. Drug Des Devel Ther. 2013;7:1359-1364.

124. Novak G, Fox N, Clegg S, et al. Changes in brain volume doi: 10.2147/DDDT.S53401
with bapineuzumab in mild to moderate Alzheimer’s 135. Klein G, Delmar P, Voyle N, et al. Gantenerumab reduces
disease. J Alzheimers Dis. 2015;49(4):1123-1134. amyloid-β plaques in patients with prodromal to moderate

doi: 10.3233/JAD-150448 Alzheimer’s disease: A PET substudy interim analysis.
Alzheimers Res Ther. 2019;11(1):101.
125. Salloway S, Sperling R, Fox NC, et al. Two Phase 3 trials
of bapineuzumab in mild-to-moderate Alzheimer’s disease. doi: 10.1186/s13195-019-0559-z
N Engl J Med. 2014;370(4):322-333. 136. Ostrowitzki S, Lasser RA, Dorflinger E, et al. A phase
doi: 10.1056/nejmoa1304839 III randomized trial of gantenerumab in prodromal
Alzheimer’s disease. Alzheimers Res Ther. 2017;9(1):95.
126. Vandenberghe R, Rinne JO, Boada M, et al. Bapineuzumab
for mild to moderate Alzheimer’s disease in two global, doi: 10.1186/s13195-017-0318-y
randomized, phase 3 trials. Alzheimers Res Ther. 137. Bateman RJ, Cummings J, Schobel S, et al. Gantenerumab:
2016;8(1):18. An anti-amyloid monoclonal antibody with potential
doi: 10.1186/s13195-016-0189-7 disease-modifying effects in early Alzheimer’s disease.
Alzheimers Res Ther. 2022;14(1):178.
127. Abushouk AI, Elmaraezy A, Aglan A, et al. Bapineuzumab
for mild to moderate Alzheimer’s disease: A meta-analysis doi: 10.1186/s13195-022-01110-8
of randomized controlled trials. BMC Neurol. 2017;17(1):66. 138. Panza F, Solfrizzi V, Imbimbo BP, et al. Efficacy and safety
doi: 10.1186/s12883-017-0850-1 studies of gantenerumab in patients with Alzheimer’s
disease. Expert Rev Neurother. 2014;14(9):973-986.
128. Farlow M, Arnold SE, Van Dyck CH, et al. Safety and
biomarker effects of solanezumab in patients with doi: 10.1586/14737175.2014.945522
Alzheimer’s disease. Alzheimers Dement. 2012;8(4):261- 139. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of
271. amyloid removal in patients with Alzheimer disease treated
doi: 10.1016/j.jalz.2011.09.224 with gantenerumab. Arch Neurol. 2012;69(2):198-207.
129. Siemers ER, Friedrich S, Dean RA, et al. Safety and changes doi: 10.1001/archneurol.2011.1538
in plasma and cerebrospinal fluid amyloid beta after a single 140. Bohrmann B, Baumann K, Benz J, et al. Gantenerumab:
administration of an amyloid beta monoclonal antibody A novel human anti-Aβ antibody demonstrates sustained
in subjects with Alzheimer disease. Clin Neuropharmacol. cerebral amyloid-β binding and elicits cell-mediated removal
2010;33(2):67-73. of human amyloid-β. J Alzheimers Dis. 2012;28(1):49-69.

doi: 10.1097/WNF.0b013e3181cb577a doi: 10.3233/JAD-2011-110977
130. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of 141. Retout S, Gieschke R, Serafin D, Weber C, Frey N,
solanezumab for mild-to-moderate Alzheimer’s disease. Hofmann C. Disease modeling and model-based meta-
N Engl J Med. 2014;370(4):311-321. analyses to define a new direction for a phase III program of
gantenerumab in Alzheimer’s disease. Clin Pharmacol Ther.
doi: 10.1056/nejmoa1312889
2022;111(4):857-866.
131. Willis BA, Sundell K, Lachno DR, et al. Central
pharmacodynamic activity of solanezumab in mild doi: 10.1002/cpt.2535
Alzheimer’s disease dementia. Alzheimers Dement (N Y). 142. Yang P, Sun F. Aducanumab: The first targeted Alzheimer’s
2018;4:652-660. therapy. Drug Discov Ther. 2021;15(3):166-168.
doi: 10.1016/j.trci.2018.10.001 doi: 10.5582/ddt.2021.01061

Volume 3 Issue 1 (2024) 15 https://doi.org/10.36922/an.2058